Literature DB >> 17461896

Factors determining adequacy of axillary node dissection in breast cancer patients.

Anees B Chagpar1, Charles R Scoggins, Robert C G Martin, Sunati Sahoo, David J Carlson, Alison L Laidley, Souzan E El-Eid, Terre Q McGlothin, Kelly M McMasters.   

Abstract

With increased focus on quality assurance, a complete axillary lymph node dissection (ALND) has been defined as the removal of 10 or more lymph nodes (LN). The objective of this study was to determine which patient, physician, and geographic factors predict the adequacy of ALND in breast cancer patients. The University of Louisville Breast Cancer Sentinel Lymph Node Study is a multicenter, prospective study of 4,131 patients, all of whom had a sentinel node biopsy and completion ALND. Univariate and multivariate analyses were performed to determine which factors were independently associated with the removal of 10 or more LN. Of the 4,131 patients in this study, the median number of LN removed was 11 (range; 3-45). Ten or more LN were removed in 3,213 (77.8%) patients. The median patient age in this study was 60 (range; 27-100), with a median tumor size of 1.5 cm (range; 0.1-11.0 cm). On univariate analysis, patient age, tumor size, and palpability were correlated with adequacy of ALND. Academic affiliation and percentage of breast practice were significant physician factors predictive of adequacy of ALND. Both geographic region and community size were significantly correlated with adequacy of ALND. On multivariate analysis, patient age (p = 0.024), surgeon academic affiliation (p < 0.001), percentage breast practice (p < 0.001), and community size (p = 0.003) were significant determinants of adequacy of ALND. Younger patients were more likely to have an adequate ALND. Surgeons in academic practice had a higher rate of adequate ALND, as did those practicing in larger communities. Surgeons with a more breast experience had a lower rate of adequate ALND. Patient age, surgeon academic affiliation, and breast experience, as well as community size are all significant factors predictive of adequacy of ALND.

Entities:  

Mesh:

Year:  2007        PMID: 17461896     DOI: 10.1111/j.1524-4741.2007.00415.x

Source DB:  PubMed          Journal:  Breast J        ISSN: 1075-122X            Impact factor:   2.431


  9 in total

1.  Sentinel Node Biopsy in Special Histologic Types of Invasive Breast Cancer.

Authors:  Montserrat Solà; Mireia Recaj; Eva Castellà; Pere Puig; Josep Maria Gubern; Juan Francisco Julian; Manel Fraile
Journal:  J Breast Health       Date:  2016-04-01

2.  Prereferral head and neck cancer treatment: compliance with national comprehensive cancer network treatment guidelines.

Authors:  Carol M Lewis; Amy C Hessel; Dianna B Roberts; Yunxia Z Guo; F Christopher Holsinger; Lawrence E Ginsberg; Adel K El-Naggar; Randal S Weber
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2010-12

3.  Surgeon specialization and use of sentinel lymph node biopsy for breast cancer.

Authors:  Tina W F Yen; Purushuttom W Laud; Rodney A Sparapani; Ann B Nattinger
Journal:  JAMA Surg       Date:  2014-02       Impact factor: 14.766

4.  Remnant uptake as a postoperative oncologic quality indicator.

Authors:  David F Schneider; Kristin A Ojomo; Herbert Chen; Rebecca S Sippel
Journal:  Thyroid       Date:  2013-07-17       Impact factor: 6.568

5.  Lymph node ratio predicts recurrence in papillary thyroid cancer.

Authors:  David F Schneider; Haggi Mazeh; Herbert Chen; Rebecca S Sippel
Journal:  Oncologist       Date:  2013-01-23

Review 6.  Prognostic factors in elderly patients with breast cancer.

Authors:  Alessandro Cappellani; Maria Di Vita; Antonio Zanghì; Andrea Cavallaro; Gaetano Piccolo; Marcello Majorana; Giuseppina Barbera; Massimiliano Berretta
Journal:  BMC Surg       Date:  2013-10-08       Impact factor: 2.102

7.  Lymphangiogenesis and lymphatic metastasis in breast cancer.

Authors:  Sophia Ran; Lisa Volk; Kelly Hall; Michael J Flister
Journal:  Pathophysiology       Date:  2009-12-24

8.  Axillary Lymph Node Dissection Rates and Prognosis From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer.

Authors:  Sungchan Gwark; Woo Chul Noh; Sei Hyun Ahn; Eun Sook Lee; Yongsik Jung; Lee Su Kim; Wonshik Han; Seok Jin Nam; Gyungyub Gong; Seon-Ok Kim; Hee Jeong Kim
Journal:  Front Oncol       Date:  2021-09-30       Impact factor: 6.244

9.  Outcomes after Treatment of Metaplastic Versus Other Breast Cancer Subtypes.

Authors:  Amy C Moreno; Yan Heather Lin; Isabelle Bedrosian; Yu Shen; Gildy V Babiera; Simona F Shaitelman
Journal:  J Cancer       Date:  2020-01-01       Impact factor: 4.207

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.